Gastrotech Pharma AS was founded in 2003 around IP generated by the University of Gothenburg in Sweden. It came about after a meeting between the partners at venture capital firm Nordic Biotech, and the management of Sahltech AB, a holding company set up to commercialize IP generated by the Sahlgrenska Academy, Gothenburg University's medical faculty, and the Karolinska Institute in Stockholm. (Sahltech also cultivated much of the IP behind stem cell firm Cell Therapeutics, now known as Cellartis AB .)
Gastrotech's surprisingly advanced pipeline--it has two Phase II programs—is focused on gastro-intestinal (GI) disorders including irritable bowel syndrome (IBS) and the GI aspects of catabolic conditions such as cachexia. But...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?